Manufacturing and the Market: Rationalizing the Shortage of Bacillus Calmette-Guérin.
Bandari J., Maganty A., MacLeod LC., Davies BJ.
Bacillus Calmette-Guérin (BCG) is used as first-line intravesical therapy following tumor resection of non-muscle-invasive bladder cancer. Primary producers of BCG announced shortages within the last decade, leading to a worldwide shortage. We review the literature examining the BCG shortage and propose solutions to cope with this problem.